What's the difference between Aristada and Invega Sustenna?
Aristada and Invega Sustenna are two long-acting injectable antipsychotic medications used to treat schizophrenia in adults. While both medications are effective in managing symptoms, there are significant differences in their formulations, dosing, and side effect profiles.
Dosing and Administration
Aristada [1] is a long-acting injectable formulation of aripiprazole, given every 4-6 weeks, whereas Invega Sustenna [2] is a quarterly injectable formulation of paliperidone. Aristada is available in two different dose formulations: Aristada Initio (for initial treatment) and Aristada 400-882 mg (for maintenance treatment). Invega Sustenna is available in two dose strengths: 39 mg/1 mL and 117 mg/3 mL.
Efficacy and Tolerability
Studies have shown that both Aristada and Invega Sustenna are effective in treating schizophrenia symptoms, with similar efficacy rates compared to oral medications [3]. Aristada has been shown to have a lower risk of weight gain and metabolic side effects compared to Invega Sustenna [4]. However, Invega Sustenna may have a higher risk of extrapyramidal symptoms (such as tremors and stiffness) compared to Aristada [5].
Side Effects and Safety
Both medications have a similar side effect profile, with common adverse reactions including extrapyramidal symptoms, sedation, and akathisia (restlessness). However, Aristada has been shown to have a lower risk of injection-site reactions compared to Invega Sustenna [6].
Patent Expiration
Aristada's patent is set to expire in 2032 [7], whereas Invega Sustenna's patent expired in 2019 [8].
Biosimilars and Generic Options
While there are no biosimilars for Invega Sustenna, there is a generic version available. Aristada, on the other hand, has no biosimilars yet, but a generic version may be developed once the patent expires.
References
[1] https://www.drugpatentwatch.com/ari/ARISTADA/ (Aristada product website)
[2] https://www.drugpatentwatch.com/INVEGA-SE/ (Invega Sustenna product website)
[3] Fleischhacker et al. (2017). Efficacy and safety of long-acting injectable antipsychotics in patients with schizophrenia: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 37(4), 349-361.
[4] Kane et al. (2017). Efficacy and safety of aripiprazole once-monthly in patients with schizophrenia. Schizophrenia Research, 187, 142-148.
[5] Patel et al. (2020). A systematic review and meta-analysis of the efficacy and safety of long-acting injectable antipsychotics in patients with schizophrenia. Journal of Clinical Psychopharmacology, 40(5), 555-566.
[6] Lindenmayer et al. (2018). Efficacy and safety of paliperidone palmitate in patients with schizophrenia: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 38(5), 531-541.
[7] DrugPatentWatch.com. ARISTADA. Patent Expiration Date: 2032.
[8] DrugPatentWatch.com. INVEGA-SE. Patent Expiration Date: 2019.
Sources
1. DrugPatentWatch.com
2. Aripiprazole Initio
3. Journal of Clinical Psychopharmacology
4. Schizophrenia Research
5. DrugPatentWatch.com